Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
14,242
Stocks News & Analysis
stocks
Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure
stocks
OpenAI missed multiple revenue targets - here’s why it likely won’t IPO this year
stocks
Lower production and higher prices for ASX hydrocarbon play
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,970.00 | 5.90 | -0.07% |
| CAC 40 | 8,114.84 | 0.00 | 0.00% |
| DAX 40 | 24,292.38 | 337.82 | 1.41% |
| Dow JONES (US) | 49,652.14 | 790.33 | 1.62% |
| FTSE 100 | 10,378.82 | 165.71 | 1.62% |
| HKSE | 25,776.53 | 335.31 | -1.28% |
| NASDAQ | 24,892.31 | 219.07 | 0.89% |
| Nikkei 225 | 59,653.62 | 368.70 | 0.62% |
| NZX 50 Index | 12,961.65 | 58.34 | 0.45% |
| S&P 500 | 7,209.01 | 73.06 | 1.02% |
| S&P/ASX 200 | 8,749.90 | 1.10 | -0.01% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |